Mannkind reported $59.56M in Current Liabilities for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Liabilities Change
Adma Biologics ADMA:US $ 28.07M 3.5M
Chemocentryx CCXI:US $ 76.08M 7.27M
Dynavax Technologies DVAX:US $ 345.2M 121M
Eli Lilly And LLY:US $ 15620.6M 2234.6M
Halozyme Therapeutics HALO:US $ 199.51M 87.82M
Immunogen IMGN:US $ 87.07M 2.95M
Insmed INSM:US $ 113.82M 11.43M
JAZZ PHA JAZZ:US $ 705.44M 31.97M
Karyopharm Therapeutics KPTI:US $ 62.54M 3.8M
Macrogenics MGNX:US $ 50.88M 16.22M
Mannkind MNKD:US $ 59.56M 6.07M
Minerva Neurosciences NERV:US $ 3.41M 0.16M
Novavax NVAX:US $ 2156.24M 104.77M
Novo Nordisk A Fs NVO:US $ 109655M 14053M
Peregrine Pharmaceuticals PPHM:US $ 93.34M 17.58M
Xencor XNCR:US $ 75.04M 14.1M